ReCor Medical Archives - Page 2 of 2 - Medical Design Sourcing

4 major cardiology trends you need to know from TCT 2022

Medtronic, Edwards and Abbott presented positive data as TAVR, TEER and renal denervation innovations continue to arrive.

The 34th Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Boston this past week and a ton of big names made waves with their technologies and innovations.

Medtronic, Abbott, Edwards and Boston Scientific represent a few of the companies revealing new data for their cardiovascular offerings. ReCor Medical, Abiomed and more got involved, too.

Plenty of the study outcomes represented positive steps forward, while other companies hit speed bumps in their efforts. Here are some of the biggest takeaways from the conference:

1. Renal denervation innovations plug along

Medtronic (NYSE:MDT) announced study data that demonstrates significant blood pressure reduction with the Symplicity renal denervation system.

The RDN minimally invasive procedure delivers radiofrequency energy to specific nerves near the …

ReCor Medical ultrasound renal denervation trial meets primary efficacy endpoint

This ReCor Medical illustration shows the Paradise renal denervation catheter during the procedure. The red circle indicates ultrasound-generated energy producing heat for denervation, while the blue circles illustrate cooling from circulating water within the artery to protect the artery from heat.

ReCor Medical announced that a trial for its Paradise ultrasound renal denervation (uRDN) treatment met its primary efficacy endpoint.

Palo Alto, California-based ReCor’s RADIANCE II pivotal trial evaluated Paradise as a treatment for hypertension. The trial operated under FDA investigational device exemption. Results were presented at TCT 2022 in Boston. They follow the company’s July announcement that Paradise met its primary endpoints in the same trial.

The randomized, sham-controlled pivotal trial evaluated 224 patients with uncontrolled hypertension. Patients, randomized 2:1 for uRDN or sham, had to remain off antihypertensive medications throughout…

ReCor Medical, Otsuka say renal denervation system met primary endpoint in U.S. study

This ReCor Medical illustration shows the Paradise renal denervation catheter during the procedure. The red circle indicates ultrasound-generated energy producing heat for denervation, while the blue circles illustrate cooling from circulating water within the artery to protect the artery from heat.

ReCor Medical and Otsuka Medical Devices today announced positive results from a trial of its renal denervation system for hypertension.

The Radiance II U.S. FDA investigational device exemption (IDE) pivotal trial evaluating the Paradise ultrasound renal denervation (uRDN) system as a treatment for hypertension met its primary efficacy endpoint, demonstrating a statistically significant reduction in daytime ambulatory systolic blood pressure between treatment and a sham procedure measured at two months.

ReCor Medical designed its Paradise platform as a device-based, minimally invasive procedure for treating high blood pressure. The procedure usually takes less than…

ReCor Medical completes enrollment in renal denervation trial for treating hypertension

This ReCor Medical illustration shows the Paradise renal denervation catheter during the procedure. The red circle indicates ultrasound-generated energy producing heat for denervation, while the blue circles illustrate cooling from circulating water within the artery to protect the artery from heat.

ReCor Medical announced today that it completed enrollment in its Radiance-II pivotal trial of the Paradise ultrasound renal denervation (uRDN) system.

The Radiance-II trial of the Paradise uRDN system will evaluate the platform in the treatment of uncontrolled hypertension in patients on zero-to-two antihypertensive oral medications.

ReCor Medical designed its Paradise platform as a device-based, minimally invasive procedure for treating high blood pressure. The procedure usually takes less than an hour, with the Paradise catheter placed in the renal artery.

Palo Alto, California-based ReCor Medical said in a news release that, subject to study outcomes, Rad…

ReCor Medical’s ultrasound renal denervation system launches in Europe

This ReCor Medical illustration shows the Paradise renal denervation catheter during the procedure. The red circle indicates ultrasound-generated energy producing heat for denervation, while the blue circles illustrate cooling from circulating water within the artery to protect the artery from heat.

ReCor Medical announced today that it launched its Paradise ultrasound renal denervation system in Germany.

Palo Alto, California-based ReCor said in a news release that it made its Paradise system available for treating uncontrolled hypertension, with Heart Center Leipzig and Saarland University Hospital (Homburg/Saar).

The company designed its Paradise platform as a device-based, minimally invasive procedure for treating high blood pressure. The procedure usually takes less than an hour, with the Paradise catheter placed in the renal artery.

Usually, three doses of ultrasound energy lasting a few seconds are applied to each of the main arteries leading to t…

Is renal denervation back as a high blood pressure treatment?

The Symplicity Spyral renal denervation system delivers energy to the nerves leading to the kidneys, which help regulate blood pressure. [Image courtesy of Medtronic]Medtronic (NYSE:MDT) today reported clinically significant and sustained blood pressure reduction among nearly 3,000 people with uncontrolled hypertension treated with the company’s Symplicity renal denervation system.

The study results, reported today out of the 2021 EuroPCR Annual Meeting, come the same week as ReCor Medical touted its own positive renal denervation study at the American College of Cardiology’s 70th Annual Scientific Session.

Together, the new research suggests that renal denervation could be back as a promising medical technology in the cardiovascular space — half a decade after Medtronic announced a major clinical trial had failed to meet its efficacy endpoint. Since the Symplicity HTN-3 study’s failure, Medtronic has sought trial designs that clear up confounding factors su…

5 of the latest cardiac tech insights out of ACC.21

The American College of Cardiology’s 70th Annual Scientific Session has produced some positive news about some controversial cardiac tech.

Drug-coated stents, which a 2018 study linked to late-stage death, were shown to be non-inferior to non-drug-coated stents in patients with peripheral arterial disease. And a new study of renal denervation that used a different methodology showed significant progress in reducing high blood pressure.

Get the full story on our sister site, Medical Design & Outsourcing.

ReCor Medical has positive renal denervation study news

This ReCor Medical illustration shows the Paradise renal denervation catheter during the procedure. The red circle indicates ultrasound-generated energy producing heat for denervation, while the blue circles illustrate cooling from circulating water within the artery to protect the artery from heat.

ReCor Medical‘s renal denervation significantly reduced blood pressure among people with drug-resistant hypertension, according to a new study reported at the American College of Cardiology’s 70th Annual Scientific Session.

The study news, announced yesterday, could suggest a turnaround in fortunes for renal denervation technology. One considered the next big thing in the medical device industry, renal denervation took a hit in the middle of the 2010s when Medtronic announced a major clinical trial had failed to meet its efficacy endpoint.

Get the full story on our sister site MassDevice.